- 12 abstracts for four compounds accepted including: new results from head-to-head trials comparing 2nd-generation EGFR TKI, afatinib, with 1st-generation EGFR TKIs, gefitinib and erlotinib
- Updated data for 3rd-generation EGFR TKI, BI 1482694, showing strong anti-tumour activity and favourable safety profile in patients whose tumours have progressed on initial EGFR TKI treatment
- Further data for triple angiokinase inhibitor nintedanib and IGF-1/IGF-2 co-neutralising mAb, BI 836845
INGELHEIM, Germany -- (BUSINESS WIRE) --
Boehringer Ingelheim today announced that the latest data from its oncology portfolio will be presented at the ESMO Asia 2015 Congress in Singapore, 18-21 December 2015. New data for BI 1482694* (HM61713**) demonstrate a strong anti-tumour activity (confirmed objective response and disease control rates) with a favourable safety profile in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) whose tumours have acquired the most common mechanism of resistance, the T790M mutation, and have stopped responding to treatment with previous 1st- and/or 2nd-generation EGFR targeted therapies. BI 1482694 is a novel, 3rd-generation, EGFR mutant-specific tyrosine kinase inhibitor (TKI).
Dr Mehdi Shahidi, Medical Head, Solid Tumour Oncology, Boehringer Ingelheim commented, “We are looking forward to presenting the exciting new data from our oncology portfolio at ESMO Asia 2015 Congress. The results of the two head-to-head trials of afatinib versus 1st-generation TKIs, gefitinib and erlotinib, could provide guidance to the practicing oncologist on the choice of TKIs in EGFR-mutated and squamous cell lung cancer, respectively. We are also excited to present the latest results for BI 1482694, Boehringer Ingelheim’s newest compound, as we strive to extend the continuum of treatment with targeted therapies for patients with EGFR-mutated lung cancer and delay the burdensome side effects of chemotherapy for even longer.”
Data for Boehringer Ingelheim Oncology Compounds at ESMO Asia 2015 Congress
|
Title |
|
Authors |
|
Abstract Details |
|
|
BI 1482694* |
|||||
|
Clinical activity and safety of the EGFR |
|
Jong-Seok Lee, Keunchil Park, |
|
Date: Saturday 19 December Time: 16.30–17.30 Location: Hall 332 Abstract: 425PD Poster Discussion Session |
|
|
Phase II study of BI1482694 in patients |
|
Pasi A. Jänne, Jeewoong Son, |
|
Date: Sunday 20 December Time: 13.30–14.15 Location: Exhibition and Poster Area Abstract: 476TiP Poster Display Session |
|
|
Afatinib*** |
|||||
|
Second-line afatinib vs methotrexate |
|
Makoto Tahara, Ezra E. W. |
|
Date: Friday 18 December Time: 14.30–14.40 Location: Hall 332 Abstract: 3140 Proffered Paper Session Abstract available at time of presentation |
|
|
Afatinib (A) vs gefitinib (G) as first-line |
|
Keunchil Park, Eng-Huat Tan, Li |
|
Date: Sunday 20 December Time: 16.30–16.45 Location: Hall 406 Abstract: LBA2 Proffered Paper Session Abstract available at time of presentation |
|
|
Phase III trial of afatinib vs erlotinib in |
|
Keunchil Park, Wei Li, Caicun |
|
Date: Sunday 20 December Time: 13.30-14.15 Location: Exhibition and poster area Abstract: 443P Poster Display Session |
|
|
Afatinib (A) versus chemotherapy (CT) |
|
Yi-Long Wu, Lecia V Sequist, |
|
Date: Sunday 20 December Time: 13.30-14.15 Location: Exhibition and poster area Abstract: 446P Poster Display Session |
|
|
Overall survival (OS) with afatinib (A) vs |
|
Yi-Long Wu, Lecia V Sequist , |
|
Date: Sunday 20 December Time: 13.30-14.15 Location: Exhibition and poster area Abstract: 445P Poster Display Session |
|
|
Phase IV study of afatinib as second-line |
|
Sumitra Thongprasert, Aurelia |
|
Date: Sunday 20 December Time: 13.30-14.15 Location: Exhibition and poster area Abstract: 477TiP Poster Display Session |
|
|
Phase III study of afatinib vs methotrexate |
|
Ping Zhang Tang, Myung-Ju Ahn,
|
|
Date: Sunday 20 December Time: 13.30-14.15 Location: Exhibition and poster area Abstract: 340TiP Poster Display Session |
|
|
Phase III study of afatinib vs placebo as |
|
Chao Su Hu, Anthony Chan, Li |
|
Date: Sunday 20 December Time: 13.30-14.15 Location: Exhibition and poster area Abstract: 339TiP Poster Display Session |
|
|
Nintedanib**** |
|||||
|
Efficacy of nintedanib/docetaxel in East |
|
Yi-Long Wu, Ying Cheng, Bong-Seog |
|
Date: Sunday 20 December Time: 13.50-14.15 Location: Exhibition and poster area Abstract: 438P Poster Display Session |
|
|
BI 836845***** |
|||||
|
Phase Ib trial of afatinib and BI 836845 |
|
Daniel Shao Weng Tan, Chia-Chi |
|
Date: Sunday 20 December Time: 13.30-14.15 Location: Exhibition and poster area Abstract: 479TiP Poster Display Session |
|
*BI 1482694 is an investigational, novel, oral, 3rd-generation, EGFR mutant-specific tyrosine kinase inhibitor (TKI) developed to specifically target tumours with EGFR mutations including the resistance mutation T790M.
**Boehringer Ingelheim has an exclusive license and collaboration agreement with Hanmi Pharmaceutical Co. Ltd for the development and global commercialisation rights (except South Korea, China and Hong Kong) of BI 1482694 (HM61713).
***Afatinib is approved in a number of markets, including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF® and in the US under the brand name GILOTRIF® for use in patients with distinct types of EGFR mutation-positive NSCLC. Registration conditions differ internationally, please refer to locally approved prescribing information. Afatinib is under regulatory review by health authorities in other countries worldwide. Afatinib is not approved in other indications.
****Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. Nintedanib is under regulatory review by health authorities in other countries outside the EU. Nintedanib is not approved in other oncology indications.
*****BI 836845, is an investigational, IGF ligand-neutralizing antibody that binds to both IGF-1 and IGF-2 and neutralises growth-promoting signaling.
#
Intended audiences:
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.
For notes to editors please visit:
View source version on businesswire.com: http://www.businesswire.com/news/home/20151218005186/en/
CONTACT:
Boehringer Ingelheim
Corporate Communications
Media + PR
Dr. Reinhard Malin
Phone: +49 6132 – 77 90815
Fax: +49 6132 – 77 6601
Email: press@boehringer-ingelheim.com
or
Further Media Channels
www.facebook.com/boehringeringelheim
www.twitter.com/Boehringer
www.youtube.com/user/boehringeringelheim
